After successful catheter ablation for AF, rivaroxaban did not reduce a composite of stroke or systemic embolism vs. aspirin at 36 mo

Resultado clave

After successful AF catheter ablation, rivaroxaban did not reduce stroke or systemic embolism compared to aspirin at 36 months.

Puntos clave

• The study aims to evaluate the effectiveness of rivaroxaban compared to aspirin in reducing the risk of stroke or systemic embolism after catheter ablation for atrial fibrillation (AF).
• Conducted a comparative analysis between rivaroxaban and aspirin.
• Followed patients for 36 months post-catheter ablation.
• Monitored incidence of stroke and systemic embolism.
• Rivaroxaban did not significantly reduce the composite risk of stroke or systemic embolism compared to aspirin.
• Both medications showed similar effectiveness over the 36-month period.